Sponsored by:

AHA Scientific Sessions 2011

November 12-16, 2011 - Orlando, FL

Note that some of these links take you to a site outside of CardioSource.
CardioSource does not assume responsibility for content of external sites.

Monday November 21 2011

  • Cardiologists Headed Home With Practice Changes in Sight

    ORLANDO — Practice will change based on trial results both positive and negative that emerged here at the American Heart Association meeting, as this exclusive InFocus report explains.

  • Women Prone to 'Broken Hearts'

    ORLANDO — Women were nine times more likely to develop takotsubo cardiomyopathy, or "broken heart syndrome" than men, and older women more likely than younger, researchers found.

Friday November 18 2011

  • Ablation Stops Paroxysmal Afib

    ORLANDO — First-line treatment of paroxysmal atrial fibrillation with catheter-based radiofrequency ablation gives patients more long-term relief from the cardiac rhythm disturbances than drug therapy, researchers suggested here.

  • Blood Type Tied to Stroke Risk

    ORLANDO — The conventional stroke risks such as hypertension and smoking are well known, but researchers have now found that blood type, particularly the ABO blood group, is also related to the risk of stroke.

Thursday November 17 2011

  • Wrap-up of AHA 2011

    Dr. Christopher Cannon discusses the highlights of trials presented at AHA 2011, including ATLAS ACS 2-TIMI 51, Post-MI FREEE, SATURN, AIM-HIGH and Evacetrapib.

  • Fear of ICD Shock Fries Sex Life

    ORLANDO — The notion of experiencing a shock from an implantable-cardioverter defibrillator (ICD) during sex is enough to hamper performance in the bedroom among men with congenital heart disease, according to a study presented here at the American Heart Association meeting.

  • Low Vitamin D May Harm Arteries in Kids

    ORLANDO — Vitamin D deficiency may have damaging vascular effects in children with a high cardiovascular risk, a single-center study showed.

Wednesday November 16 2011

Tuesday November 15 2011


    Extended-Release Niacin Does Not Reduce Clinical Events in Patients with Established Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled with Statin Therapy

  • Evacetrapib Dose Ranging Study

    Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or in Combination with the Most Commonly-Used Statins


    Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens with Different HDL Effects

  • Afib Stroke Risk Follows Heart Transplant

    ORLANDO — Atrial fibrillation was present in a significant portion of perioperative heart transplant patients and correlated with a higher complication rate including stroke, according to a single-center study.

  • Intracardiac Cell Therapy Hits and Misses

    ORLANDO — Whether intracardiac cell infusions can help repair the heart muscle after an MI could depend on the type of cells and when they are delivered, according to two studies presented here.

  • Primary Care POWERed for Weight Loss

    ORLANDO — Participants in primary care-based weight-loss behavioral intervention programs achieved and sustained clinically significant weight loss at two years, according to results from the POWER trial.

  • Same-Time Afib Ablation Okay for Seniors

    ORLANDO — Older patients seemed to handle surgical atrial fibrillation ablation during other cardiac procedures as well as younger patients, researchers said here.

  • Vital Elements Often Missing from Sports Physicals

    ORLANDO — Compliance with American Heart Association guidelines for pre-participation screening for cardiovascular abnormalities in young athletes is poor, a survey in Washington state showed.

Monday November 14 2011

Sunday November 13 2011

Friday November 11 2011

  • All Kids Need Cholesterol Tests, AAP Says

    ORLANDO — Cholesterol checks should be part of periodic well-child visits for all children, according to new guidelines from the American Academy of Pediatrics.

  • Center Stage Again Belongs to Antithrombotics

    ORLANDO — With new contenders in field, the antithrombotic arena is likely to again steal the spotlight here at the American Heart Association meeting.